STAT News· Katherine MacPhail·· 4 hours agoPickScore66
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
In brief
AI drug developer Pathos announced a $237 million Series E round led by Bristol Myers Squibb, at a valuation of about $3 billion. The company will use Tempus AI data and partner with BMS to expand from oncology into neurological diseases such as Alzheimer's. Its proprietary model, Foundry, runs thousands of agents that compute the probability of success for clinical assets, guiding drug selection, population choice, and trial design.
Why it matters
BMS led a $237 million Series E, valuing Pathos at $3 billion as it uses Tempus data to expand into Alzheimer's.
Source: STAT News · statnews.com